“We observed that the majority of our trastuzumab resistant cell lines remain sensitive to lapatinib, providing further evidence that these two agents have independent mechanisms of resistance.

This study describes a second combination demonstrating the efficacy of lapatinib and chemotherapy in patients with HER2-overexpressing metastatic breast cancer (in addition to the previously ...